Tags

Type your tag names separated by a space and hit enter

More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Diabetes Obes Metab. 2018 09; 20(9):2314-2318.DO

Abstract

The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan-Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P < .0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P < .0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.

Authors+Show Affiliations

National Research Institute, Los Angeles, California.Germans Trias i Pujol Research Institute, UAB, Badalona, Spain. CIBERDEM and CIBERER, Madrid, Spain.Department of Internal Medicine, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas.Department of Translational Medicine, Federico II University School of Medicine, Naples, Italy.BDM Consulting, Inc., Somerset, New Jersey.PRO Unlimited, Inc., Boca Raton, Florida.Brigham and Women's Hospital, Boston, Massachussetts.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29785837

Citation

Frias, Juan, et al. "More Patients Reach Glycaemic Control With a Fixed-ratio Combination of Insulin Glargine and Lixisenatide (iGlarLixi) Than With Basal Insulin at 12 Weeks of Treatment: a Post Hoc Time-to-control Analysis of LixiLan-O and LixiLan-L." Diabetes, Obesity & Metabolism, vol. 20, no. 9, 2018, pp. 2314-2318.
Frias J, Puig Domingo M, Meneghini L, et al. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. Diabetes Obes Metab. 2018;20(9):2314-2318.
Frias, J., Puig Domingo, M., Meneghini, L., Napoli, R., Liu, M., Soltes Rak, E., & Aroda, V. R. (2018). More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. Diabetes, Obesity & Metabolism, 20(9), 2314-2318. https://doi.org/10.1111/dom.13368
Frias J, et al. More Patients Reach Glycaemic Control With a Fixed-ratio Combination of Insulin Glargine and Lixisenatide (iGlarLixi) Than With Basal Insulin at 12 Weeks of Treatment: a Post Hoc Time-to-control Analysis of LixiLan-O and LixiLan-L. Diabetes Obes Metab. 2018;20(9):2314-2318. PubMed PMID: 29785837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. AU - Frias,Juan, AU - Puig Domingo,Manuel, AU - Meneghini,Luigi, AU - Napoli,Raffaele, AU - Liu,Minzhi, AU - Soltes Rak,Erika, AU - Aroda,Vanita R, Y1 - 2018/06/13/ PY - 2018/02/01/received PY - 2018/04/24/revised PY - 2018/05/02/accepted PY - 2018/5/23/pubmed PY - 2019/2/6/medline PY - 2018/5/23/entrez KW - GLP-1 KW - glycaemic control KW - insulin therapy KW - type 2 diabetes SP - 2314 EP - 2318 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 20 IS - 9 N2 - The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan-Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P < .0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P < .0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/29785837/More_patients_reach_glycaemic_control_with_a_fixed_ratio_combination_of_insulin_glargine_and_lixisenatide__iGlarLixi__than_with_basal_insulin_at_12_weeks_of_treatment:_A_post_hoc_time_to_control_analysis_of_LixiLan_O_and_LixiLan_L_ L2 - https://doi.org/10.1111/dom.13368 DB - PRIME DP - Unbound Medicine ER -